Vir Biotechnology, Inc.

What they do

Vir Biotechnology operates as a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. Its lead programs target chronic hepatitis delta (CHD) and multiple dual-masked T-cell engagers (TCEs) for solid tumors, with a preclinical portfolio in infectious diseases and oncology. The company relies on third-party manufacturers for clinical and commercial supply and does not own large-scale manufacturing facilities.

Revenue drivers

• Collaboration revenue — Historically, revenue was primarily from collaborations, such as the prior COVID-19 partnership; annual revenue declined from $1.62B in 2022 to $68.6M in 2025.
• No product revenue — The company has no approved or commercialized products; all product candidates are in clinical or preclinical stages, so revenue is not derived from product sales.
• Astellas collaboration — Closed a global strategic collaboration with Astellas to develop VIR-5500, potentially including upfront and milestone payments, but financial terms were not disclosed in the excerpts.

Recent performance

Revenue for the second quarter of 2026 was $238.9M, up from $64.1M in the prior quarter, driven by a one-time transaction (likely collaboration-related). The company reported a net loss of $438.0M for full-year 2025, improving from a $522.0M loss in 2024. Operating cash flow was negative $391.8M in 2025. Cash and investments exceeded $1.0 billion as of June 30, 2026. The company ended the quarter with total assets of $1.21B and shareholders' equity of $982.5M.

Strategy

Management's stated priorities are advancing the ECLIPSE registrational program for CHD and progressing the Phase 1 TCE portfolio in oncology. The company is collaborating with Astellas on VIR-5500 to co-develop the program and has initiated multiple dose-expansion cohorts. It is also making preclinical assets available for external partnerships, including influenza and COVID antibodies. The company is investing in clinical development and manufacturing scale-up with third-party partners.

Risks

• Clinical and regulatory failure — Successful development and regulatory approval of product candidates, including the ECLIPSE program and TCEs, are uncertain; failure would prevent commercialization and revenue generation.
• Dependence on third parties — The company relies on third-party manufacturers for clinical and future commercial supplies, and delays or shortages could limit access to supplies.
• Continued net losses and funding needs — The company expects to incur net losses in the foreseeable future and may need substantial additional funding, which could be dilutive or require relinquishing rights.
• Regulatory and pricing pressure — If approved, healthcare reforms and reimbursement changes could lower product prices, and non-compliance with anti-corruption laws could lead to penalties.

Outlook

Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026, with ECLIPSE 2 and 3 data expected in the first quarter of 2027. The company anticipates initiating pivotal Phase 3 trials for VIR-5500 in 2027. VIR-5818 dose-escalation data are expected in the second half of 2026. Management expects continued net losses and significant research and development spending.